HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Research Dictionary Pharma Mobile

Sign Up FREE or Login

TV 1901

Subscribe to New Research on TV 1901

structure in first source

Also Known As:

N-valproyl glycinamide; N-valproylglycinamide; TV-1901; VPGD cpd; Valrocemide

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Amino Acids: 10808
  - Glycine: 3656
    - TV 1901: 2

Experts

1.	Hovinga, Collin A: 1 article (01/2004)
2.	White, H S: 1 article (07/2001)
3.	Woodhead, J H: 1 article (07/2001)
4.	Isoherranen, N: 1 article (07/2001)
5.	Bialer, M: 1 article (07/2001)

Related Diseases

1.	Epilepsy (Aura) 01/01/2004 - "Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy. " 01/01/2004 - "In October 2003, a phase II trial using valrocemide as an adjunct therapy in refractory epilepsy patients had been completed and phase III trials were being planned. " 07/01/2001 - "We sought to investigate the anticonvulsant activity of the new antiepileptic drug (AED), valrocemide or TV1901 (VGD) in various animal (rodent) models of human epilepsy to determine its anticonvulsant profile and safety margin. "
2.	Neuralgia (Stump Neuralgia) 01/01/2004 - "Valrocemide was also being investigated for potential utility in the treatment of bipolar disorder and neuropathic pain."
3.	Bipolar Disorder (Mania) 01/01/2004 - "Valrocemide was also being investigated for potential utility in the treatment of bipolar disorder and neuropathic pain."